Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Rating) – Equities research analysts at B. Riley issued their FY2023 earnings estimates for Longboard Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 26th. B. Riley analyst K. Patel expects that the company will earn ($2.24) per share for the year. B. Riley has […]
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical-stage biopharmaceutical company specialized in developing innovative treatments for cardiovascular emergencies